www.chicorporate.com/BiomarkerSymposia_Content.aspx?id= -
[Cached Version]
Published on: 5/13/2009
Last Visited: 5/16/2009
Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
...
Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
Dr. Patterson returned to Amgen Inc., California in 2003 and is an Executive Director in the Medical Sciences function leading the Molecular Sciences department (with the Computational Biology department also reporting to him).
Medical Sciences is responsible for conducting first-in-human studies through to Phase 2a for all therapeutic areas in the company, and Molecular Sciences is part of this function to enable biochemical determination of whether the targeted pathway is being interdicted, whether exposure:response relationships can be generated (to inform dose ranging), and in which patient populations the therapeutic may be more efficacious (should that be necessary).
He is well known in the field of protein chemistry, and a pioneer in the field of proteomics.
He has published extensively and is a frequent guest lecturer.
After leaving Amgen in 2000, he served as Vice President of Proteomics at the Celera Genomics Group and then as Chief Scientific Officer of Farmal Biomedicines, LLC.
While at Celera, he established the company's initial foray into protein-based drug target discovery and validation in oncology, building a large group of cell biologists, protein chemists and mass spectrometrists whose efforts resulted in the identification of cell surface targets for therapeutic development and diagnostics, a number of which have been licensed to Pharma and Biotechnology companies.
Dr. Patterson first worked at Amgen from 1993â€"2000 progressing from a Research Scientist to Department Head, ultimately leading the Department of Biochemistry and Genetics.
128 online sources [ view sources ]
Profile is not claimed [ claim profile ]
